This Department of Defense (DoD) grant supports the initial exploration of innovative, high-risk, and potentially groundbreaking concepts in neurofibromatosis and Schwannomatosis research. This grant is for investigators to pursue serendipitous observations and generate scientific rationale for new hypotheses or establish initial principles of innovative hypotheses. Preliminary data is encouraged but not required, with a strong emphasis on clearly articulating novelty. Projects involving human subjects are limited to those qualifying for exempt or expedited review; clinical trials are explicitly excluded. The DoD encourages proposals addressing critical needs such as neurofibromatosis complications with high mortality or morbidity, refinement of imaging techniques and molecular markers, and translational research, including preclinical testing of therapeutic agents.
Opportunity ID: 52270
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-10-NFRP-EHDA |
| Funding Opportunity Title: | DoD Neurofibromatosis Exploration – Hypothesis Development Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 02, 2010 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | May 20, 2010 |
| Current Closing Date for Applications: | May 20, 2010 |
| Archive Date: | Jun 19, 2010 |
| Estimated Total Program Funding: | $750,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The NFRP Exploration Hypothesis Development Award (EHDA) mechanism was first offered in FY08. Since that time, 46 EHDA applications have been received, and 13 have been recommended for funding. The EHDA supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the neurofibromatosis and/or Schwannomatosis research fields. Results of studies conducted through this award may provide the scientific rationale upon which a new hypothesis can be based, or they should provide initial principles of an innovative hypothesis. This award is designed to provide investigators with the opportunity to pursue serendipitous observations. The presentation of preliminary data is encouraged, but not required. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate how the proposed research is innovative and how the concept is novel. DOD FY10 Neurofibromatosis Exploration Hypothesis Development Award 3 Because these awards are designed for preliminary investigations, projects involving human subjects or specimens will not be supported unless they are exempt under 32 CFR 219.101(b) or eligible for expedited review (32 CFR 219.110 or 21 CFR 56.110). Additional information on the protection of human subjects and exempt or expedited review status may be found at https://www.bids.tswg.gov/TSWG/bids.nsf/5DD5E2BA50F02C18852572B1005F5B8B/$file/Title_32_CFR_Part_219.pdf. Applications proposing studies that do not qualify for exempt or expedited review status will be administratively withdrawn. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. Areas of Encouragement: The FY10 NFRP encourages research proposals that specifically address the critical needs of the NF community in the following areas: Complications of NF with high mortality such as neoplasms and cerebrovascular abnormalities; Complications of NF with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects, and pain; Refinement and standardization of imaging techniques, molecular and cellular markers, and quality of life metrics for use in future clinical trials; and Translational research such as the development or preclinical testing of therapeutic agents for the treatment of NF. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil
eReceipt HELP: 301-682-5507; help@cdmrp.org Email:cdmrp.pa@amedd.army.mil |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 52270 Full Announcement-1 -> fy10 cdmrp detailed budget and justification form-1.pdf
Folder 52270 Full Announcement-1 -> fy10 cdmrp biosketch-1.pdf
Folder 52270 Full Announcement-1 -> nfrp_fy10 ehda pa_gg.pdf
Packages
| Agency Contact Information: | PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil eReceipt HELP: 301-682-5507; help@cdmrp.org Email: cdmrp.pa@amedd.army.mil |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00016817 | Mar 02, 2010 | May 20, 2010 | View |
Package 1
Mandatory forms
52270 RR_SF424_1_2-1.2.pdf
52270 PerformanceSite_1_4-1.4.pdf
52270 RR_KeyPersonExpanded_1_2-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
